Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Extended-therapy duration for chronic hepatitis C, genotype 1: the long and the short of it.

World journal of gastroenterology - 21 Jun 2008

Pearlman Brian L

Abstract excerpt

With pegylated interferon and ribavirin, more than half of all chronically-infected hepatitis C patients can achieve a sustained virologic response; however, patients with genotype 1 infections and those with other poor prognostic factors have relatively inferior treatment response rates. Since new therapies are still years away from approval, it is incumbent upon providers to maximize the therapeutic efficacy of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Administration Schedule
Share to Drug Therapy, Combination
Share to Hepatitis C, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Patient Selection

Share to Polyethylene Glycols

Share to Ribavirin

Source

Open in PubMed Open full text

Identifiers

PMID: 18595128
DOI: 10.3748/wjg.14.3621
PMCID: PMC2719224

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Extended-therapy duration for chronic hepatitis C, genotype 1: the long and the short of it.PMID 18595128Read ↗

Chronic hepatitis C therapy: changing the rules of duration.Semantic proximity Read ↗

Optimal treatment duration for patients with HCV genotype 1 infection.Semantic proximity Read ↗

Standard Versus Extended Duration Direct-Acting Antiviral Therapy in Hepatitis C Patients With Slow Response to Treatment.Semantic proximity Read ↗

Reducing treatment duration in patients infected with hepatitis C genotype 1: any need for further studies?Semantic proximity Read ↗

Prolonged PEG-IFN and RBV is effective in patients with HCV genotype 1 and high viral load who achieved virological response later than 24 weeks.Semantic proximity Read ↗

Expert opinion on the treatment of patients with chronic hepatitis C.Semantic proximity Read ↗

Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis.Semantic proximity Read ↗

A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus.Semantic proximity Read ↗

Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders.Semantic proximity Read ↗

Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future.Semantic proximity Read ↗

Clinical trial: extended treatment duration of peginterferon-alpha2b plus ribavirin for 72 and 96 weeks in hepatitis C genotype 1-infected late responders.Semantic proximity Read ↗

Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.